BCL9 and cancer: As disruption of the BCL9–β-catenin interaction inhibits Wnt activation [154], which has been proposed as a therapeutic target for cancer [155,156], it remains to be tested if increasing BCL9 levels or fine-tuning WNT signaling could reverse the deficits caused by 1q21 CNV.